Details of the Drug Combination

General Information of Drug Combination (ID: DCKX38X)

Drug Combination Name

Crizotinib Mitomycin

Indication

Disease Entry	Status	REF
Pleural epithelioid mesothelioma	Investigative	[1]

Component Drugs

Crizotinib DM4F29C

Mitomycin DMH0ZJE

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: NCI-H226

Zero Interaction Potency (ZIP) Score: 4

Bliss Independence Score: 12.27

Loewe Additivity Score: 8.29

LHighest Single Agent (HSA) Score: 12.04

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Crizotinib

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[2]

Crizotinib Interacts with 4 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Modulator	[9]
ALK tyrosine kinase receptor (ALK)	TTPMQSO	ALK_HUMAN	Modulator	[9]
Proto-oncogene c-Ros (ROS1)	TTSZ6Y3	ROS1_HUMAN	Modulator	[9]
HGF/Met signaling pathway (HGF/Met pathway)	TTKA5LP	NOUNIPROTAC	Inhibitor	[10]
------------------------------------------------------------------------------------

Crizotinib Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[12]
------------------------------------------------------------------------------------

Crizotinib Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[13]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[13]
------------------------------------------------------------------------------------

Crizotinib Interacts with 45 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[14]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Activity	[15]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Increases Response To Substance	[7]
ALK tyrosine kinase receptor (ALK)	OTV3P4V8	ALK_HUMAN	Decreases Response To Substance	[16]
Prominin-1 (PROM1)	OTBHV8NX	PROM1_HUMAN	Decreases Expression	[6]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Decreases Expression	[6]
Epithelial cell adhesion molecule (EPCAM)	OTHBZK5X	EPCAM_HUMAN	Decreases Expression	[6]
Cytidine deaminase (CDA)	OT3HXP6N	CDD_HUMAN	Decreases Expression	[6]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Increases Expression	[17]
Acyl-CoA 6-desaturase (FADS2)	OTUX531P	FADS2_HUMAN	Increases Expression	[17]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Increases Expression	[17]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[17]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[17]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[17]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)	OTCO26FV	HMCS1_HUMAN	Increases Expression	[17]
Sterol regulatory element-binding protein 2 (SREBF2)	OTBXUNPL	SRBP2_HUMAN	Increases Expression	[17]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[17]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Increases Phosphorylation	[17]
Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)	OT6KFNMS	CAC1C_HUMAN	Decreases Activity	[17]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Decreases Activity	[17]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[7]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Expression	[7]
Follitropin subunit beta (FSHB)	OTGLS283	FSHB_HUMAN	Decreases Secretion	[18]
Lutropin subunit beta (LHB)	OT5GBOVJ	LSHB_HUMAN	Decreases Secretion	[18]
Tyrosine-protein kinase Lck (LCK)	OT883FG9	LCK_HUMAN	Decreases Activity	[19]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[20]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[21]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Phosphorylation	[20]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Increases Secretion	[22]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Phosphorylation	[23]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Phosphorylation	[23]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Phosphorylation	[24]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Phosphorylation	[25]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1)	OTZRWTGA	IQGA1_HUMAN	Decreases Phosphorylation	[26]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Decreases Phosphorylation	[25]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[7]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Cleavage	[27]
Echinoderm microtubule-associated protein-like 4 (EML4)	OTJC45TA	EMAL4_HUMAN	Increases Mutagenesis	[23]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Decreases Activity	[15]
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Decreases Response To Substance	[28]
Pro-epidermal growth factor (EGF)	OTANRJ0L	EGF_HUMAN	Decreases Response To Substance	[24]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Response To Substance	[28]
Mast/stem cell growth factor receptor Kit (KIT)	OTHUY3VZ	KIT_HUMAN	Decreases Response To Substance	[16]
Proheparin-binding EGF-like growth factor (HBEGF)	OTLU00JS	HBEGF_HUMAN	Decreases Response To Substance	[24]
Protransforming growth factor alpha (TGFA)	OTPD1LL9	TGFA_HUMAN	Decreases Response To Substance	[24]
------------------------------------------------------------------------------------


⏷ Show the Full List of 45 DOT(s)

Indication(s) of Mitomycin

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[3]
Gastrointestinal cancer	2C11	Approved	[3]
Pancreatic adenocarcinoma	N.A.	Approved	[4]
Solid tumour/cancer	2A00-2F9Z	Approved	[5]
Urinary bladder cancer	N.A.	Approved	[4]
Urinary bladder neoplasm	N.A.	Approved	[4]
Urinary system neoplasm	N.A.	Approved	[4]
Urinary tract disease	GC2Z	Approved	[4]
Bladder disease	DC11-DC1Z	Investigative	[4]
Colon cancer	2B90.Z	Investigative	[4]

Mitomycin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[35]
------------------------------------------------------------------------------------

Mitomycin Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[36]
------------------------------------------------------------------------------------

Mitomycin Interacts with 274 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[37]
Alternative prion protein (PRNP)	OTE85L1Q	APRIO_HUMAN	Increases Expression	[38]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Increases Expression	[38]
HLA class I histocompatibility antigen, C alpha chain (HLA-C)	OTV38BUJ	HLAC_HUMAN	Decreases Expression	[38]
Bone morphogenetic protein 4 (BMP4)	OTPZMDFH	BMP4_HUMAN	Decreases Expression	[38]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Expression	[38]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Increases Expression	[38]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[38]
DNA ligase 1 (LIG1)	OTEEQS43	DNLI1_HUMAN	Decreases Expression	[38]
Nuclear transcription factor Y subunit alpha (NFYA)	OTWFFOVH	NFYA_HUMAN	Increases Expression	[38]
Ephrin type-A receptor 2 (EPHA2)	OTI6QNX2	EPHA2_HUMAN	Decreases Expression	[38]
Replication factor C subunit 4 (RFC4)	OTWALD2R	RFC4_HUMAN	Decreases Expression	[38]
Matrix metalloproteinase-14 (MMP14)	OT9C197Z	MMP14_HUMAN	Decreases Expression	[38]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1)	OTK71JYU	TCP4_HUMAN	Increases Expression	[38]
Small ribosomal subunit protein eS1 (RPS3A)	OTUEP7CL	RS3A_HUMAN	Increases Expression	[38]
Microtubule-associated protein RP/EB family member 1 (MAPRE1)	OTCVQD60	MARE1_HUMAN	Increases Expression	[38]
Histone-binding protein RBBP7 (RBBP7)	OTLB56HX	RBBP7_HUMAN	Increases Expression	[38]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[39]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1)	OTEAUJXN	TRIA1_HUMAN	Increases Expression	[40]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Increases Expression	[40]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[40]
Heat shock cognate 71 kDa protein (HSPA8)	OTJI2RCI	HSP7C_HUMAN	Increases Expression	[40]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Increases Expression	[40]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[40]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[40]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Increases Expression	[40]
DNA damage-binding protein 2 (DDB2)	OTO8HVVB	DDB2_HUMAN	Increases Expression	[40]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Decreases Expression	[41]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1)	OTDG5VW7	SDHF1_HUMAN	Decreases Expression	[30]
Serine/threonine-protein kinase Sgk1 (SGK1)	OT301T1U	SGK1_HUMAN	Decreases Expression	[30]
E3 ubiquitin-protein ligase TRIM38 (TRIM38)	OT6SP1M9	TRI38_HUMAN	Decreases Expression	[30]
Torsin-1A (TOR1A)	OTYCLGJU	TOR1A_HUMAN	Decreases Expression	[30]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Decreases Expression	[42]
Serine/threonine-protein kinase Chk1 (CHEK1)	OTTTI622	CHK1_HUMAN	Increases Phosphorylation	[43]
Transcription factor EC (TFEC)	OTUST8MR	TFEC_HUMAN	Decreases Expression	[30]
Regulator of G-protein signaling 16 (RGS16)	OTBKZASI	RGS16_HUMAN	Decreases Expression	[30]
E3 ubiquitin-protein ligase RNF113A (RNF113A)	OTR6N7HU	R113A_HUMAN	Decreases Expression	[30]
HMG box-containing protein 1 (HBP1)	OTDPGGDV	HBP1_HUMAN	Decreases Expression	[30]
Kinesin-like protein KIF20A (KIF20A)	OTXOQHE0	KI20A_HUMAN	Decreases Expression	[30]
Myelin protein zero-like protein 1 (MPZL1)	OTJSUUHR	MPZL1_HUMAN	Decreases Expression	[30]
Serine/threonine-protein kinase Chk2 (CHEK2)	OT8ZPCNS	CHK2_HUMAN	Increases Phosphorylation	[43]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Increases Expression	[44]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Increases Expression	[45]
Thymidine kinase, cytosolic (TK1)	OTY5JFM1	KITH_HUMAN	Increases Mutagenesis	[46]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Increases Expression	[45]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Expression	[45]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Expression	[47]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Increases Expression	[44]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Activity	[48]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[49]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Increases Expression	[50]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Increases Expression	[49]
CD59 glycoprotein (CD59)	OTSUMQDH	CD59_HUMAN	Increases Mutagenesis	[51]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[52]
Beta-galactosidase (GLB1)	OTB0TKAG	BGAL_HUMAN	Increases Activity	[45]
rRNA 2'-O-methyltransferase fibrillarin (FBL)	OTRODIE5	FBRL_HUMAN	Affects Localization	[53]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Decreases Expression	[30]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[54]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[55]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[55]
GTP cyclohydrolase 1 (GCH1)	OTOZ6NSL	GCH1_HUMAN	Decreases Expression	[30]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Expression	[56]
Replication factor C subunit 1 (RFC1)	OT3L5PK3	RFC1_HUMAN	Decreases Expression	[30]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[57]
RNA-binding protein 34 (RBM34)	OTX3LUGI	RBM34_HUMAN	Decreases Expression	[30]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Expression	[54]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[45]
LIM/homeobox protein Lhx2 (LHX2)	OTK61NP8	LHX2_HUMAN	Decreases Expression	[30]
DNA mismatch repair protein Msh6 (MSH6)	OT46FP09	MSH6_HUMAN	Decreases Expression	[30]
RecQ-like DNA helicase BLM (BLM)	OTEJOAJX	BLM_HUMAN	Decreases Expression	[30]
Ataxin-1 (ATXN1)	OTQF0HNR	ATX1_HUMAN	Decreases Expression	[30]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[56]
Ras-related protein Rap-2b (RAP2B)	OTD2NDQP	RAP2B_HUMAN	Decreases Expression	[30]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Increases Secretion	[57]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Expression	[58]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Decreases Expression	[30]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Increases Expression	[59]
Protein kinase C zeta type (PRKCZ)	OTN2FE42	KPCZ_HUMAN	Increases Cleavage	[57]
DNA repair protein RAD51 homolog 1 (RAD51)	OTNVWGC1	RAD51_HUMAN	Increases Expression	[55]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Decreases Expression	[50]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[60]
Tripartite motif-containing protein 26 (TRIM26)	OTS0DJIP	TRI26_HUMAN	Decreases Expression	[30]
E3 ubiquitin-protein ligase TRIM32 (TRIM32)	OTJOV0PG	TRI32_HUMAN	Decreases Expression	[30]
Chromatin assembly factor 1 subunit A (CHAF1A)	OTXSSY4H	CAF1A_HUMAN	Decreases Expression	[30]
Chromatin assembly factor 1 subunit B (CHAF1B)	OTOMK4KH	CAF1B_HUMAN	Decreases Expression	[30]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Decreases Expression	[59]
Protein BTG3 (BTG3)	OT9ANHVT	BTG3_HUMAN	Decreases Expression	[30]
Histone RNA hairpin-binding protein (SLBP)	OTVYYQRT	SLBP_HUMAN	Decreases Expression	[30]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[57]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI)	OTR443C5	BGH3_HUMAN	Decreases Expression	[60]
Neutral amino acid transporter B(0) (SLC1A5)	OTE2H26Q	AAAT_HUMAN	Decreases Expression	[30]
Protein MCM10 homolog (MCM10)	OTV0O3JN	MCM10_HUMAN	Decreases Expression	[30]
Partner and localizer of BRCA2 (PALB2)	OT6DNDBG	PALB2_HUMAN	Decreases Expression	[30]
Leucine-rich repeat-containing protein 47 (LRRC47)	OTSE8NAO	LRC47_HUMAN	Decreases Expression	[30]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Increases Expression	[56]
Cytochrome c oxidase assembly factor 7 (COA7)	OTRQJYL6	COA7_HUMAN	Decreases Expression	[30]
Mitochondrial potassium channel (CCDC51)	OTOJNHNA	MITOK_HUMAN	Decreases Expression	[30]
Integrator complex subunit 15 (INTS15)	OT3O4INM	INT15_HUMAN	Decreases Expression	[30]
Krueppel-like factor 6 (KLF6)	OTQY9S7F	KLF6_HUMAN	Decreases Expression	[30]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Decreases Expression	[30]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[30]
Protein orai-3 (ORAI3)	OTUP3OH3	ORAI3_HUMAN	Decreases Expression	[30]
Protein pelota homolog (PELO)	OTF3WLIM	PELO_HUMAN	Decreases Expression	[30]
TIMELESS-interacting protein (TIPIN)	OT9PZHXV	TIPIN_HUMAN	Decreases Expression	[30]
Fanconi anemia group D2 protein (FANCD2)	OTVEB5LF	FACD2_HUMAN	Increases Ubiquitination	[43]
tRNA pseudouridine(38/39) synthase (PUS3)	OT6WG6M2	PUS3_HUMAN	Decreases Expression	[30]
Transmembrane protein 185B (TMEM185B)	OTGNYS0J	T185B_HUMAN	Decreases Expression	[30]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2)	OT3Q11WQ	I20L2_HUMAN	Decreases Expression	[30]
GrpE protein homolog 1, mitochondrial (GRPEL1)	OT8O00YJ	GRPE1_HUMAN	Decreases Expression	[30]
Forkhead box protein J2 (FOXJ2)	OTPT639J	FOXJ2_HUMAN	Decreases Expression	[30]
Homologous-pairing protein 2 homolog (PSMC3IP)	OT9UB5UO	HOP2_HUMAN	Decreases Expression	[30]
rRNA methyltransferase 2, mitochondrial (MRM2)	OTRYA1HU	MRM2_HUMAN	Decreases Expression	[30]
Frizzled-1 (FZD1)	OTZATHVS	FZD1_HUMAN	Decreases Expression	[30]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Affects Response To Substance	[33]
Tripartite motif-containing protein 2 (TRIM2)	OT0V1YVC	TRIM2_HUMAN	Affects Response To Substance	[33]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Affects Response To Substance	[33]
Fanconi-associated nuclease 1 (FAN1)	OT1LM1HZ	FAN1_HUMAN	Increases Response To Substance	[61]
Replication factor C subunit 3 (RFC3)	OT1MS7AO	RFC3_HUMAN	Affects Response To Substance	[33]
CD9 antigen (CD9)	OT2184XU	CD9_HUMAN	Affects Response To Substance	[33]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1)	OT2E7A6W	KANK1_HUMAN	Affects Response To Substance	[33]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Affects Response To Substance	[33]
Mitochondrial fission 1 protein (FIS1)	OT2HL10J	FIS1_HUMAN	Affects Response To Substance	[33]
Cytoplasmic aconitate hydratase (ACO1)	OT2VUR7L	ACOHC_HUMAN	Affects Response To Substance	[33]
Syncytin-2 (ERVFRD-1)	OT3064D7	SYCY2_HUMAN	Affects Response To Substance	[33]
Protein FAM171A1 (FAM171A1)	OT33BHEP	F1711_HUMAN	Affects Response To Substance	[33]
Sister chromatid cohesion protein PDS5 homolog A (PDS5A)	OT34P56Z	PDS5A_HUMAN	Affects Response To Substance	[33]
Excitatory amino acid transporter 3 (SLC1A1)	OT3B9M6W	EAA3_HUMAN	Affects Response To Substance	[33]
Syntabulin (SYBU)	OT3FQV7N	SYBU_HUMAN	Affects Response To Substance	[33]
Fatty acid CoA ligase Acsl3 (ACSL3)	OT3MWER1	ACSL3_HUMAN	Affects Response To Substance	[33]
Prelamin-A/C (LMNA)	OT3SG7ZR	LMNA_HUMAN	Affects Response To Substance	[33]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Increases Response To Substance	[62]
Pyridoxal kinase (PDXK)	OT40AJ5J	PDXK_HUMAN	Affects Response To Substance	[33]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Affects Response To Substance	[33]
Diamine acetyltransferase 1 (SAT1)	OT52AU22	SAT1_HUMAN	Affects Response To Substance	[33]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Increases Response To Substance	[63]
Neprilysin (MME)	OT5Q39P8	NEP_HUMAN	Affects Response To Substance	[33]
Lymphokine-activated killer T-cell-originated protein kinase (PBK)	OT5Z27TW	TOPK_HUMAN	Affects Response To Substance	[33]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2)	OT6MFOWF	TGM2_HUMAN	Affects Response To Substance	[33]
G-protein-signaling modulator 2 (GPSM2)	OT6RPMRM	GPSM2_HUMAN	Affects Response To Substance	[33]
Dual specificity protein phosphatase 4 (DUSP4)	OT6WAO12	DUS4_HUMAN	Affects Response To Substance	[33]
Interferon-induced GTP-binding protein Mx1 (MX1)	OT6X8G5T	MX1_HUMAN	Increases Response To Substance	[64]
Plasminogen activator inhibitor 2 (SERPINB2)	OT72QLZB	PAI2_HUMAN	Affects Response To Substance	[33]
Transcriptional regulator ATRX (ATRX)	OT77RSQW	ATRX_HUMAN	Affects Response To Substance	[33]
Monocarboxylate transporter 7 (SLC16A6)	OT7BIIZX	MOT7_HUMAN	Affects Response To Substance	[33]
Ras-related protein Rab-17 (RAB17)	OT7NBUGQ	RAB17_HUMAN	Affects Response To Substance	[33]
Stanniocalcin-2 (STC2)	OT86YP8G	STC2_HUMAN	Affects Response To Substance	[33]
Pirin (PIR)	OT8ALXHU	PIR_HUMAN	Affects Response To Substance	[33]
Myelin proteolipid protein (PLP1)	OT8CM9CX	MYPR_HUMAN	Affects Response To Substance	[33]
Protein-S-isoprenylcysteine O-methyltransferase (ICMT)	OT8CNKBO	ICMT_HUMAN	Affects Response To Substance	[33]
G0/G1 switch protein 2 (G0S2)	OT8FL49L	G0S2_HUMAN	Affects Response To Substance	[33]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform (PPP2R5E)	OT8GPFT5	2A5E_HUMAN	Decreases Response To Substance	[65]
cAMP-dependent protein kinase inhibitor alpha (PKIA)	OT8M5GVO	IPKA_HUMAN	Affects Response To Substance	[33]
Melanoma-associated antigen 12 (MAGEA12)	OT8ULELL	MAGAC_HUMAN	Affects Response To Substance	[33]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A)	OT9297OG	2ABA_HUMAN	Decreases Response To Substance	[65]
Tissue factor pathway inhibitor (TFPI)	OTA0FX16	TFPI1_HUMAN	Affects Response To Substance	[33]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2)	OTAKUO27	ACOT2_HUMAN	Affects Response To Substance	[33]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Affects Response To Substance	[66]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1)	OTB06ESI	ACSL1_HUMAN	Affects Response To Substance	[33]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Affects Response To Substance	[33]
Cochlin (COCH)	OTBEHD89	COCH_HUMAN	Affects Response To Substance	[33]
ETS domain-containing protein Elk-3 (ELK3)	OTBM9BHT	ELK3_HUMAN	Affects Response To Substance	[33]
High mobility group protein HMGI-C (HMGA2)	OTBMBHHL	HMGA2_HUMAN	Affects Response To Substance	[33]
Protein PRRC2C (PRRC2C)	OTBX3MXM	PRC2C_HUMAN	Affects Response To Substance	[33]
Melanocyte protein PMEL (PMEL)	OTCDDHHM	PMEL_HUMAN	Affects Response To Substance	[33]
BMP and activin membrane-bound inhibitor homolog (BAMBI)	OTCEJ8W5	BAMBI_HUMAN	Affects Response To Substance	[33]
Creatine kinase U-type, mitochondrial (CKMT1A)	OTCINHH5	KCRU_HUMAN	Affects Response To Substance	[33]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1)	OTCJ458Q	AT1A1_HUMAN	Affects Response To Substance	[33]
CD166 antigen (ALCAM)	OTCO4LP7	CD166_HUMAN	Affects Response To Substance	[33]
Cytochrome c oxidase copper chaperone (COX17)	OTCP4LH2	COX17_HUMAN	Affects Response To Substance	[33]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Decreases Response To Substance	[67]
Collagen alpha-3(IX) chain (COL9A3)	OTCUJOEK	CO9A3_HUMAN	Affects Response To Substance	[33]
A-kinase anchor protein 12 (AKAP12)	OTCVRDDX	AKA12_HUMAN	Affects Response To Substance	[33]
Dystrophin (DMD)	OTD21T5J	DMD_HUMAN	Affects Response To Substance	[33]
Dickkopf-related protein 3 (DKK3)	OTDU94EY	DKK3_HUMAN	Affects Response To Substance	[33]
dTDP-D-glucose 4,6-dehydratase (TGDS)	OTEOFLOS	TGDS_HUMAN	Affects Response To Substance	[33]
Calmegin (CLGN)	OTEWVFQV	CLGN_HUMAN	Affects Response To Substance	[33]
Ras association domain-containing protein 1 (RASSF1)	OTEZIPB7	RASF1_HUMAN	Increases Response To Substance	[68]
Protocadherin Fat 1 (FAT1)	OTF174DH	FAT1_HUMAN	Affects Response To Substance	[33]
Midkine (MDK)	OTF24HKC	MK_HUMAN	Affects Response To Substance	[33]
Serine/arginine-rich splicing factor 1 (SRSF1)	OTF61HOV	SRSF1_HUMAN	Affects Response To Substance	[33]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PPP2R5C)	OTF7CGO2	2A5G_HUMAN	Increases Response To Substance	[65]
G antigen 7 (GAGE7)	OTF8BTR9	GAGE7_HUMAN	Affects Response To Substance	[33]
Serglycin (SRGN)	OTFAVSX0	SRGN_HUMAN	Affects Response To Substance	[33]
Catenin alpha-1 (CTNNA1)	OTFC725Z	CTNA1_HUMAN	Affects Response To Substance	[33]
Sortilin (SORT1)	OTFCQ4B1	SORT_HUMAN	Affects Response To Substance	[33]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Affects Response To Substance	[33]
Myelin basic protein (MBP)	OTFZCEDB	MBP_HUMAN	Affects Response To Substance	[33]
Tudor domain-containing protein 3 (TDRD3)	OTG83E2C	TDRD3_HUMAN	Affects Response To Substance	[33]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Affects Response To Substance	[33]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Affects Response To Substance	[33]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Response To Substance	[69]
Sigma intracellular receptor 2 (TMEM97)	OTH76ZWK	SGMR2_HUMAN	Affects Response To Substance	[33]
Transmembrane protein 156 (TMEM156)	OTH7YJID	TM156_HUMAN	Affects Response To Substance	[33]
Probable JmjC domain-containing histone demethylation protein 2C (JMJD1C)	OTHAWK8C	JHD2C_HUMAN	Affects Response To Substance	[33]
Unconventional myosin-X (MYO10)	OTHB78ZQ	MYO10_HUMAN	Affects Response To Substance	[33]
Tribbles homolog 2 (TRIB2)	OTHSX3MX	TRIB2_HUMAN	Affects Response To Substance	[33]
Actin-binding LIM protein 1 (ABLIM1)	OTHXEK3E	ABLM1_HUMAN	Affects Response To Substance	[33]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Affects Response To Substance	[33]
Protein S100-A11 (S100A11)	OTI57KDN	S10AB_HUMAN	Affects Response To Substance	[33]
Protein S100-A10 (S100A10)	OTI71243	S10AA_HUMAN	Affects Response To Substance	[33]
Melanoma-associated antigen 6 (MAGEA6)	OTI8S0O2	MAGA6_HUMAN	Affects Response To Substance	[33]
Runt-related transcription factor 3 (RUNX3)	OTITK1XD	RUNX3_HUMAN	Increases Response To Substance	[70]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Affects Response To Substance	[33]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Affects Response To Substance	[33]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Affects Response To Substance	[33]
Trefoil factor 3 (TFF3)	OTJJDRTU	TFF3_HUMAN	Affects Response To Substance	[33]
Collagen alpha-2(IV) chain (COL4A2)	OTJK1LKN	CO4A2_HUMAN	Affects Response To Substance	[33]
Hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1)	OTJQL0I3	HEY1_HUMAN	Affects Response To Substance	[33]
E3 ubiquitin-protein ligase MYLIP (MYLIP)	OTL0PFGV	MYLIP_HUMAN	Affects Response To Substance	[33]
Hematopoietically-expressed homeobox protein HHEX (HHEX)	OTLIUVYX	HHEX_HUMAN	Affects Response To Substance	[33]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2)	OTLNA39Z	NMT2_HUMAN	Affects Response To Substance	[33]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Increases Response To Substance	[71]
Protein S100-A4 (S100A4)	OTLRGFSQ	S10A4_HUMAN	Affects Response To Substance	[33]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Affects Response To Substance	[33]
Bridging integrator 3 (BIN3)	OTMIWWDW	BIN3_HUMAN	Affects Response To Substance	[33]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Affects Response To Substance	[33]
Four and a half LIM domains protein 1 (FHL1)	OTN535SU	FHL1_HUMAN	Affects Response To Substance	[33]
Cysteine-rich hydrophobic domain-containing protein 2 (CHIC2)	OTNE3T6Z	CHIC2_HUMAN	Affects Response To Substance	[33]
Inositol monophosphatase 2 (IMPA2)	OTNFB9YN	IMPA2_HUMAN	Affects Response To Substance	[33]
Neural cell adhesion molecule L1 (L1CAM)	OTNWAQ4Y	L1CAM_HUMAN	Affects Response To Substance	[33]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Affects Response To Substance	[72]
Kynurenine--oxoglutarate transaminase 3 (KYAT3)	OTO4U2QK	KAT3_HUMAN	Affects Response To Substance	[33]
Beta-secretase 2 (BACE2)	OTO5YQVK	BACE2_HUMAN	Affects Response To Substance	[33]
Histone deacetylase 9 (HDAC9)	OTO8O0LF	HDAC9_HUMAN	Affects Response To Substance	[33]
SH3 domain-binding protein 5 (SH3BP5)	OTOOEGUJ	3BP5_HUMAN	Affects Response To Substance	[33]
Glutathione S-transferase Mu 4 (GSTM4)	OTOTF8DU	GSTM4_HUMAN	Affects Response To Substance	[33]
Ras-related protein Rab-20 (RAB20)	OTP9OOVS	RAB20_HUMAN	Affects Response To Substance	[33]
Tumor protein D52 (TPD52)	OTPKSK43	TPD52_HUMAN	Affects Response To Substance	[33]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C)	OTPL0AI1	ABC3C_HUMAN	Affects Response To Substance	[33]
Kazrin (KAZN)	OTPM7BYM	KAZRN_HUMAN	Affects Response To Substance	[33]
DNA-binding protein inhibitor ID-4 (ID4)	OTPMJ39I	ID4_HUMAN	Affects Response To Substance	[33]
Centrosomal protein of 57 kDa (CEP57)	OTPOHLIX	CEP57_HUMAN	Affects Response To Substance	[33]
Epithelial membrane protein 2 (EMP2)	OTPS2H0L	EMP2_HUMAN	Affects Response To Substance	[33]
Dermatan-sulfate epimerase (DSE)	OTQ108VJ	DSE_HUMAN	Affects Response To Substance	[33]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Affects Response To Substance	[33]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A)	OTQDYH8E	ASM3A_HUMAN	Affects Response To Substance	[33]
MAPK/MAK/MRK overlapping kinase (MOK)	OTQK7M9V	MOK_HUMAN	Affects Response To Substance	[33]
High mobility group protein HMG-I/HMG-Y (HMGA1)	OTQUSHPX	HMGA1_HUMAN	Affects Response To Substance	[33]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Affects Response To Substance	[33]
Dr1-associated corepressor (DRAP1)	OTRWLF6D	NC2A_HUMAN	Affects Response To Substance	[33]
Latent-transforming growth factor beta-binding protein 2 (LTBP2)	OTS88GSD	LTBP2_HUMAN	Affects Response To Substance	[33]
Terminal nucleotidyltransferase 5A (TENT5A)	OTSYF511	TET5A_HUMAN	Affects Response To Substance	[33]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)	OTT5JX1F	LITAF_HUMAN	Affects Response To Substance	[33]
DNA repair protein RAD51 homolog 3 (RAD51C)	OTUD6SY5	RA51C_HUMAN	Increases Response To Substance	[73]
Calcium-dependent secretion activator 2 (CADPS2)	OTV1FW0M	CAPS2_HUMAN	Affects Response To Substance	[33]
Matrilin-2 (MATN2)	OTVDR68G	MATN2_HUMAN	Affects Response To Substance	[33]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Increases Response To Substance	[71]
Ensconsin (MAP7)	OTVSSJ33	MAP7_HUMAN	Affects Response To Substance	[33]
Protein artemis (DCLRE1C)	OTW3KB1I	DCR1C_HUMAN	Decreases Response To Substance	[34]
Sorbin and SH3 domain-containing protein 1 (SORBS1)	OTWH8762	SRBS1_HUMAN	Affects Response To Substance	[33]
Protein mago nashi homolog (MAGOH)	OTWRYTOX	MGN_HUMAN	Affects Response To Substance	[33]
Urokinase-type plasminogen activator (PLAU)	OTX0QGKK	UROK_HUMAN	Affects Response To Substance	[33]
Acylamino-acid-releasing enzyme (APEH)	OTX258QE	ACPH_HUMAN	Affects Response To Substance	[33]
Hematopoietic lineage cell-specific protein (HCLS1)	OTX7WGYN	HCLS1_HUMAN	Affects Response To Substance	[33]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1)	OTX8L3M5	SAHH2_HUMAN	Affects Response To Substance	[33]
Long-chain fatty acid transport protein 3 (SLC27A3)	OTXB60L7	S27A3_HUMAN	Affects Response To Substance	[33]
Metallothionein-1E (MT1E)	OTXJKU4Y	MT1E_HUMAN	Affects Response To Substance	[33]
Arginine vasopressin-induced protein 1 (AVPI1)	OTXSBR60	AVPI1_HUMAN	Affects Response To Substance	[33]
Neuroendocrine protein 7B2 (SCG5)	OTXSJMT1	7B2_HUMAN	Affects Response To Substance	[33]
Carbamoyl-phosphate synthase , mitochondrial (CPS1)	OTXV8NSR	CPSM_HUMAN	Affects Response To Substance	[33]
Peripheral myelin protein 22 (PMP22)	OTXWYWCZ	PMP22_HUMAN	Affects Response To Substance	[33]
Kinesin-like protein KIF23 (KIF23)	OTY850JC	KIF23_HUMAN	Affects Response To Substance	[33]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B)	OTY94WRA	HM20B_HUMAN	Affects Response To Substance	[33]
Protein Niban 1 (NIBAN1)	OTYOLI12	NIBA1_HUMAN	Affects Response To Substance	[33]
LIM and calponin homology domains-containing protein 1 (LIMCH1)	OTYPC4XA	LIMC1_HUMAN	Affects Response To Substance	[33]
Galectin-3 (LGALS3)	OTYQT0ZI	LEG3_HUMAN	Affects Response To Substance	[33]
L-dopachrome tautomerase (DCT)	OTYVNTBG	TYRP2_HUMAN	Affects Response To Substance	[33]
Epithelial discoidin domain-containing receptor 1 (DDR1)	OTYW1SH8	DDR1_HUMAN	Affects Response To Substance	[33]
Tissue factor pathway inhibitor 2 (TFPI2)	OTZCRWOR	TFPI2_HUMAN	Affects Response To Substance	[33]
Suppressor of tumorigenicity 7 protein (ST7)	OTZG8RC6	ST7_HUMAN	Affects Response To Substance	[33]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Response To Substance	[71]
CTD small phosphatase-like protein (CTDSPL)	OTZJ0CZK	CTDSL_HUMAN	Affects Response To Substance	[33]
C-X-C motif chemokine 5 (CXCL5)	OTZOUPCA	CXCL5_HUMAN	Affects Response To Substance	[33]
Eukaryotic translation initiation factor 5B (EIF5B)	OTZTT22W	IF2P_HUMAN	Affects Response To Substance	[33]
------------------------------------------------------------------------------------


⏷ Show the Full List of 274 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCZR22K	SW-620	Investigative	[1]
Adult acute myeloid leukemia	DCK75OP	HL-60(TB)	Investigative	[1]
Astrocytoma	DC8MJP2	SNB-19	Investigative	[1]
Clear cell renal cell carcinoma	DCHHZZ1	TK-10	Investigative	[1]
Clear cell renal cell carcinoma	DCOJHC4	786-0	Investigative	[1]
Clear cell renal cell carcinoma	DC8NSZB	CAKI-1	Investigative	[1]
Glioblastoma	DC0KBDX	SNB-75	Investigative	[1]
Glioma	DCXDJFT	SF-268	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCVIY00	OVCAR-8	Investigative	[1]
Malignant melanoma	DCT9KT5	LOX IMVI	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCQ5A0M	SK-OV-3	Investigative	[1]
Plasma cell myeloma	DCVRCEL	RPMI-8226	Investigative	[1]
Carcinoma	DC0TRBA	RXF 393	Investigative	[74]
Carcinoma	DCWS2KT	MCF7	Investigative	[74]
Invasive ductal carcinoma	DC2ZPBJ	BT-549	Investigative	[74]
Invasive ductal carcinoma	DC312QD	HS 578T	Investigative	[74]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
4	Mitomycin FDA Label
5	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
6	Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
7	Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
8	Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012 Apr;24(4):852-8. doi: 10.1016/j.cellsig.2011.11.020. Epub 2011 Dec 8.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
10	Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
11	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
12	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
13	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
14	Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013 Feb;41(2):343-52.
15	Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
16	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
17	Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
18	Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
19	Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
20	ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
21	Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
22	Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
23	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.
24	Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2.
25	Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
26	Tyrosine phosphorylation of the scaffold protein IQGAP1 in the MET pathway alters function. J Biol Chem. 2020 Dec 25;295(52):18105-18121. doi: 10.1074/jbc.RA120.015891. Epub 2020 Oct 21.
27	Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. Toxicol Lett. 2020 Feb 1;319:102-110. doi: 10.1016/j.toxlet.2019.11.007. Epub 2019 Nov 7.
28	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
29	Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
30	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
31	TCDD as a biological response modifier for Mitomycin C: oxygen tension affects enzyme activation, reactive oxygen species and cell death. Life Sci. 2006 Feb 23;78(13):1499-507. doi: 10.1016/j.lfs.2005.07.021. Epub 2005 Oct 14.
32	Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2007 Jun;27(3):285-7. doi: 10.1007/s11596-007-0317-5.
33	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
34	Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells. J Radiat Res. 2011;52(4):415-24. doi: 10.1269/jrr.10168.
35	Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
36	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
37	Mitomycin C induces multidrug resistance in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):297-304. doi: 10.1007/s00417-007-0695-1. Epub 2007 Oct 13.
38	Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
39	Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
40	Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
41	Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
42	Trace levels of mitomycin C disrupt genomic integrity and lead to DNA damage response defect in long-term-cultured human embryonic stem cells. Arch Toxicol. 2015 Jan;89(1):33-45. doi: 10.1007/s00204-014-1250-6. Epub 2014 May 18.
43	Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms. Oncotarget. 2015 Sep 22;6(28):25770-83. doi: 10.18632/oncotarget.4514.
44	Effects of mitomycin-C on normal dermal fibroblasts. Laryngoscope. 2006 Apr;116(4):514-7. doi: 10.1097/01.MLG.0000205590.62824.0A.
45	Mitomycin induces alveolar epithelial cell senescence by down-regulating GSK3 signaling. Toxicol Lett. 2021 Nov 1;352:61-69. doi: 10.1016/j.toxlet.2021.09.015. Epub 2021 Oct 5.
46	DNA polymerase kappa protects human cells against MMC-induced genotoxicity through error-free translesion DNA synthesis. Genes Environ. 2017 Jan 7;39:6. doi: 10.1186/s41021-016-0067-3. eCollection 2017.
47	In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res. 2005;115(3):219-28. doi: 10.1016/j.thromres.2004.09.001.
48	Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem. 2005 Jul 15;280(28):26193-9. doi: 10.1074/jbc.M501371200. Epub 2005 May 19.
49	Dexamethasone reduces mitomycin C-related inflammatory cytokine expression without inducing further cell death in corneal fibroblasts. Wound Repair Regen. 2010 Jan-Feb;18(1):59-69. doi: 10.1111/j.1524-475X.2009.00551.x. Epub 2009 Dec 11.
50	The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep. 2010 Jul;37(6):2693-701. doi: 10.1007/s11033-009-9801-2. Epub 2009 Sep 13.
51	Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
52	Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
53	Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
54	Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
55	Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012. Epub 2011 Jul 24.
56	Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3545-52. doi: 10.1167/iovs.04-1358.
57	Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner in human gastric adenocarcinoma cells. Cancer Lett. 2000 Oct 1;158(2):125-32. doi: 10.1016/s0304-3835(00)00489-4.
58	Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene. Toxicol Sci. 2008 Apr;102(2):232-40. doi: 10.1093/toxsci/kfm305. Epub 2007 Dec 20.
59	Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells. Cancer Lett. 2006 Jun 8;237(1):33-44. doi: 10.1016/j.canlet.2005.05.043. Epub 2005 Jul 12.
60	Mitomycin C induces apoptosis in cultured corneal fibroblasts derived from type II granular corneal dystrophy corneas. Mol Vis. 2008 Jun 30;14:1222-8.
61	FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet. 2012 Jul 8;44(8):910-5. doi: 10.1038/ng.2347.
62	O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol. 2006 Mar 1;211(2):97-105. doi: 10.1016/j.taap.2005.06.009. Epub 2005 Jul 22.
63	Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget. 2015 Sep 29;6(29):27674-87. doi: 10.18632/oncotarget.4876.
64	MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest. 1997 Dec 1;100(11):2873-80. doi: 10.1172/JCI119836.
65	PP2A-B56? complex is involved in dephosphorylation of -H2AX in the repair process of CPT-induced DNA double-strand breaks. Toxicology. 2015 May 4;331:57-65. doi: 10.1016/j.tox.2015.03.007. Epub 2015 Mar 12.
66	Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
67	Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6.
68	Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721. J Gastroenterol Hepatol. 2007 May;22(5):683-9. doi: 10.1111/j.1440-1746.2006.04676.x.
69	[Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
70	Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer. 2005 Aug 10;116(1):155-60. doi: 10.1002/ijc.20919.
71	Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
72	[Effect of adenovirus-mediated mutant exogenous P27kip1 gene expression on the chemosensitivities of cholangiocarcinoma cell line]. Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1349-52.
73	Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.
74	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.